{"title": "NewsRamp Curated News Feed for Health Wellness", "description": "NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.", "site_url": "https://www.newsramp.com", "display_name": "NewsRamp.com", "next_page": "https://feeds.newsramp.net/tldr/newsramp/moderated/20/2/health-wellness.json", "instructions": "Fine tune the feed as follows /tldr/category/newsramp/en/all/20/1/health-wellness.json /tldr/category/en/[all/moderated]/[records per page up to 100]/[page number]/health-wellness.json - Available Language Codes English=en", "prev_page": "", "current_page": 1, "total_records": 4634, "total_pages": 232, "image_url": "https://newsramp.com/light-logo.svg", "language": "en", "ttl": 10, "news": [{"feed_item_id": 30959, "prhash_id": "eed26ce8e40e6672ae56eb68c46ec1a1", "headline": "Aclarion Secures AI Patent to Revolutionize Chronic Back Pain Diagnosis", "content": "        <article>        <h1>Aclarion Secures AI Patent to Revolutionize Chronic Back Pain Diagnosis</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-4.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Aclarion Secures AI Patent to Revolutionize Chronic Back Pain Diagnosis'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Aclarion's new patent strengthens its competitive moat with AI-driven workflow automation, enabling scalable growth and enhanced gross margins in the chronic pain market.</li>            <li>The patent covers machine learning models that extract biomarkers from MRS data and implement automated quality controls for consistent, reproducible pain assessment outputs.</li>            <li>This technology helps physicians accurately identify painful spinal discs, potentially improving surgical outcomes and addressing chronic low back pain affecting millions globally.</li>            <li>Aclarion's AI platform analyzes magnetic resonance spectroscopy to distinguish painful from non-painful spinal discs, backed by 64 patents worldwide.</li>        </ul>        <h2>Why it Matters</h2>        <p>This development represents a significant advancement in personalized medicine for chronic pain management, potentially affecting millions suffering from debilitating back pain. By securing patent protection for AI-driven analysis of magnetic resonance spectroscopy data, Aclarion creates a defensible technological advantage that could accelerate clinical adoption and standardization of objective pain assessment tools. For patients, this means potentially more accurate diagnoses, reduced unnecessary procedures, and improved surgical outcomes when intervention is needed. For healthcare systems, it offers a scalable solution to a pervasive problem that costs billions annually in treatment expenses and lost productivity. The technology's ability to provide reproducible, standardized outputs across different imaging systems addresses a critical barrier to widespread implementation of objective pain assessment tools in clinical practice.</p>        <h2>Summary</h2>        <p><p>Aclarion, Inc., a commercial-stage healthcare technology company trading on Nasdaq as ACON and ACONW, has secured a significant U.S. Patent (#12,601,803) that strengthens its position in the chronic low back pain market. The patent, titled 'System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain,' specifically protects the company's machine learning platform for analyzing magnetic resonance spectroscopy (MRS) data. This intellectual property advancement covers Aclarion's use of artificial intelligence in future iterations of its flagship cloud-based platform, Nociscan, which helps physicians distinguish between painful and non-painful spinal discs by converting complex MRS spectral data into clinically actionable insights.</p><p>The newly issued patent represents a strategic milestone for Aclarion, expanding its intellectual property portfolio to 64 issued and pending patents worldwide and creating what the company describes as a 'long-term competitive moat.' According to CEO Brent Ness, the patent strengthens the foundation of their platform by protecting how they leverage AI to transform complex spectroscopy data into meaningful information that physicians can integrate into everyday practice. The technology enables automated biomarker identification, accelerated report generation, and reduced manual quality reviews\u2014capabilities that will help the company scale efficiently while enhancing already strong gross margins. Importantly, the patent also covers AI-based automated data quality controls that detect and exclude low-quality acquisition signals, ensuring consistent, reproducible outputs across different imaging systems and clinical sites.</p><p>This development matters because chronic low back pain affects approximately 266 million people worldwide, representing a significant global healthcare challenge. Aclarion's technology addresses this underserved market with evidence showing up to a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools. The patent protection enables Aclarion to build what they call a 'differentiated, software-driven platform' that could redefine how spine conditions are assessed. For those interested in learning more about the company's developments, they can visit the Latest News section on Aclarion's website or check the company's newsroom for updates relating to $ACON. The patent itself can be reviewed through the provided link to the USPTO database, offering transparency about the protected technology that could transform pain assessment methodologies.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/eed26ce8e40e6672ae56eb68c46ec1a1.30959.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/eed26ce8e40e6672ae56eb68c46ec1a1.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://prismmediawire.com'>PRISM Mediawire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/prism/en//eed26ce8e40e6672ae56eb68c46ec1a1'>Aclarion Secures AI Patent to Revolutionize Chronic Back Pain Diagnosis.</a></p></div>        </article>    ", "published": "2026-04-16T10:48:15+00:00", "audio_release": "https://cdn.newsramp.net/audio/eed26ce8e40e6672ae56eb68c46ec1a1.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/eed26ce8e40e6672ae56eb68c46ec1a1.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-4.jpg", "site_handle": "prism", "seo_description": "Aclarion secures U.S. patent for AI platform analyzing MRI data to identify painful spinal discs, expanding IP portfolio to 64 patents for chronic low back pain diagnosis technology.", "newsramp_curated": "https://newsramp.com/curated-news/aclarion-secures-ai-patent-to-revolutionize-chronic-back-pain-diagnosis/eed26ce8e40e6672ae56eb68c46ec1a1"}, {"feed_item_id": 30952, "prhash_id": "293fa383bc5a76e31f9db978e6ed4246", "headline": "GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial in 2026", "content": "        <article>        <h1>GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial in 2026</h1>        <img src='https://cdn.newsramp.app/banners/business-corporate-7.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial in 2026'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>GeoVax's GEO-MVA vaccine offers a competitive advantage by addressing global supply constraints for orthopoxvirus vaccines, potentially capturing market share through expedited regulatory pathways and strategic partnerships.</li>            <li>GeoVax plans to initiate a pivotal Phase 3 immuno-bridging study for GEO-MVA in late 2026, following regulatory alignment with EMA and completion of cGMP manufacturing for clinical-grade vaccine.</li>            <li>GEO-MVA aims to improve global public health by providing a critically needed vaccine supply for mpox and smallpox, enhancing biosecurity preparedness and protecting vulnerable populations worldwide.</li>            <li>GeoVax's GEO-MVA vaccine uses Modified Vaccinia Ankara technology to target both mpox and smallpox, representing a dual-purpose solution to address recurring outbreaks and depleted government stockpiles.</li>        </ul>        <h2>Why it Matters</h2>        <p>This development matters because it addresses a critical gap in global vaccine supply for orthopoxviruses like mpox and smallpox, which pose ongoing public health threats. Recent outbreaks have depleted government stockpiles, highlighting vulnerabilities in pandemic preparedness. GEO-MVA's accelerated regulatory pathway could provide a much-needed domestic manufacturing alternative, reducing reliance on single foreign sources and enhancing biosecurity. For populations at risk\u2014including healthcare workers, immunocompromised individuals, and those in outbreak regions\u2014this vaccine represents a potential safeguard against future epidemics. Furthermore, successful development would strengthen global health infrastructure, offering a tool for rapid response to emerging viral strains and supporting international preparedness frameworks.</p>        <h2>Summary</h2>        <p><p>GeoVax Labs, a clinical-stage biotechnology company, has announced its 2025 financial results alongside significant progress on its lead vaccine candidate, GEO-MVA. The company's primary focus is advancing this Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox, with plans to initiate a pivotal Phase 3 immuno-bridging study in the second half of 2026. This development follows regulatory alignment with the European Medicines Agency (EMA) that supports an accelerated pathway, potentially bypassing earlier trial phases. CEO David Dodd emphasized that GEO-MVA addresses critical global supply constraints for orthopoxvirus vaccines, depleted government stockpiles, and the need for diversified domestic manufacturing to enhance public health preparedness and biosecurity.</p><p>Beyond its priority program, GeoVax continues to advance a diversified pipeline including GEO-CM04S1, a next-generation COVID-19 vaccine showing promising interim results in immunocompromised populations, and Gedeptin\u00ae, an oncology therapy for head and neck cancer that has entered into an exclusive license agreement with Emory University. The company reported a net loss of $21.5 million for 2025, with decreased research expenses following the termination of a BARDA contract, and maintains a cash position of $3.1 million. For more information, visit www.geovax.com, where investors and stakeholders can find detailed corporate updates and forward-looking statements about these clinical developments.</p><p>The company's strategic positioning at the intersection of recurring mpox outbreaks, evolving viral strains, and policy-driven demand for vaccine supply diversification makes GEO-MVA potentially central to global orthopoxvirus preparedness. With manufacturing readiness established through completed cGMP production and fill-finish operations, GeoVax is actively engaging international regulatory and governmental stakeholders to align with procurement frameworks. This comprehensive approach underscores the company's commitment to addressing critical medical needs while maximizing long-term value, as detailed in their recent financial disclosures and operational highlights that signal important milestones toward potential regulatory approval and commercialization.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/293fa383bc5a76e31f9db978e6ed4246.30952.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/293fa383bc5a76e31f9db978e6ed4246.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/geovax-reports-2025-year-end-financial-results-and-provides-business-update-7086367/293fa383bc5a76e31f9db978e6ed4246'>GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial in 2026.</a></p></div>        </article>    ", "published": "2026-04-15T20:04:20+00:00", "audio_release": "https://cdn.newsramp.net/audio/293fa383bc5a76e31f9db978e6ed4246.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/293fa383bc5a76e31f9db978e6ed4246.webp", "enclosure": "https://cdn.newsramp.app/banners/business-corporate-7.jpg", "site_handle": "newmediawire", "seo_description": "GeoVax Labs announces Phase 3 trial plans for GEO-MVA mpox/smallpox vaccine in 2026, addressing global supply constraints with accelerated regulatory pathway and manufacturing readiness.", "newsramp_curated": "https://newsramp.com/curated-news/geovax-advances-mpox-smallpox-vaccine-toward-phase-3-trial-in-2026/293fa383bc5a76e31f9db978e6ed4246"}, {"feed_item_id": 30951, "prhash_id": "c6583cafc4bf9f57db625ff3726185e3", "headline": "HeartBeam Launches Public Offering to Fuel Cardiac Tech Innovation", "content": "        <article>        <h1>HeartBeam Launches Public Offering to Fuel Cardiac Tech Innovation</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-8.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='HeartBeam Launches Public Offering to Fuel Cardiac Tech Innovation'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>HeartBeam's public offering provides investment opportunity in a company advancing portable cardiac detection technology with FDA-cleared 12-lead ECG systems and AI capabilities.</li>            <li>HeartBeam is conducting a public offering to fund commercialization of its FDA-cleared 12-lead synthesized ECG system, patch development, and AI initiatives through Titan Partners.</li>            <li>HeartBeam's technology enables portable cardiac monitoring outside medical facilities, potentially improving early detection and access to care for heart conditions worldwide.</li>            <li>HeartBeam creates the first cable-free device that collects 3D ECG signals and synthesizes them into 12-lead ECGs, holding over 20 patents for this innovation.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it signals a major step in making advanced, portable cardiac monitoring widely accessible. Heart disease remains a leading cause of death globally, and traditional ECG systems often require clinical visits, delaying diagnosis. HeartBeam's technology could enable remote, real-time heart monitoring, allowing for earlier detection of conditions like arrhythmias or heart attacks. This could save lives by getting patients to treatment faster and reduce healthcare burdens through preventative care. The funding boost may accelerate the deployment of these innovations, directly impacting patients, healthcare providers, and investors in the growing digital health sector.</p>        <h2>Summary</h2>        <p><p>HeartBeam (NASDAQ: BEAT), a pioneering medical technology company focused on cardiac care innovation, has announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents. The final size and terms of this offering are subject to market conditions, with all securities to be offered by the company itself. The capital raised is intended to advance the commercialization of its groundbreaking FDA-cleared 12-lead synthesized ECG system, a core product that represents a significant leap in portable cardiac monitoring. Additionally, the net proceeds will fuel further development of its extended-wear patch and heart attack detection initiatives, enhance its artificial intelligence capabilities, and support general working capital and corporate purposes. Titan Partners, a division of American Capital Partners, is acting as the sole bookrunner for this financial move, which is detailed in the full press release available on the InvestorBrandNetwork website.</p><p>The company is at the forefront of transforming cardiac health management with its proprietary technology. HeartBeam is creating the first-ever cable-free device capable of collecting electrocardiogram (ECG) signals in three dimensions from three non-coplanar directions and synthesizing these signals into a comprehensive 12-lead ECG. This platform technology is designed for portable devices that can be used anywhere a patient is located, delivering actionable heart intelligence directly to physicians. The innovation allows healthcare providers to identify cardiac health trends and acute conditions outside traditional medical facilities, potentially directing patients to appropriate care more swiftly. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, followed by clearance for its 12-lead ECG synthesis software in December 2025. With over 20 issued patents supporting its technology enablement, HeartBeam is positioned to redefine remote cardiac monitoring. For the latest news and updates relating to BEAT, investors and interested parties can visit the company's dedicated newsroom.</p><p>This strategic financial initiative underscores HeartBeam's commitment to scaling its innovative solutions in a competitive medtech landscape. The public offering represents a critical step in funding the next phase of growth, from enhancing AI-driven diagnostics to expanding the commercial reach of its FDA-cleared systems. As forward-looking statements in the release caution, the offering involves typical market risks and uncertainties, but the intended use of proceeds highlights a clear roadmap toward improving cardiac care accessibility. The original release on www.newmediawire.com provides complete context, while the InvestorBrandNetwork website hosts essential disclaimers applicable to all published content. By leveraging this capital infusion, HeartBeam aims to accelerate its mission of bringing hospital-grade cardiac monitoring into everyday settings, potentially impacting millions of patients at risk for heart-related events.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/c6583cafc4bf9f57db625ff3726185e3.30951.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/c6583cafc4bf9f57db625ff3726185e3.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/heartbeam-beat-launches-proposed-public-offering-to-support-commercialization-and-ai-initiatives-7086366/c6583cafc4bf9f57db625ff3726185e3'>HeartBeam Launches Public Offering to Fuel Cardiac Tech Innovation.</a></p></div>        </article>    ", "published": "2026-04-15T19:30:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/c6583cafc4bf9f57db625ff3726185e3.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/c6583cafc4bf9f57db625ff3726185e3.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-8.jpg", "site_handle": "newmediawire", "seo_description": "HeartBeam announces public stock offering to fund commercialization of its FDA-cleared 12-lead ECG system and AI-driven cardiac monitoring tech, enhancing remote heart care.", "newsramp_curated": "https://newsramp.com/curated-news/heartbeam-launches-public-offering-to-fuel-cardiac-tech-innovation/c6583cafc4bf9f57db625ff3726185e3"}, {"feed_item_id": 30946, "prhash_id": "952900c048c66725e4245b57287e8e0e", "headline": "Jacksonville Family Turns Son's T1D Diagnosis Into Advocacy Powerhouse", "content": "        <article>        <h1>Jacksonville Family Turns Son's T1D Diagnosis Into Advocacy Powerhouse</h1>        <img src='https://cdn.newsramp.app/noticias-newswire/newsimage/952900c048c66725e4245b57287e8e0e.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Jacksonville Family Turns Son's T1D Diagnosis Into Advocacy Powerhouse'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Pablo's Pack T1D provides families with a strategic advantage by offering practical resources and community support to better manage Type 1 diabetes challenges.</li>            <li>The initiative works by sharing daily management experiences, providing educational resources, and organizing participation in fundraising walks to support scientific research.</li>            <li>This family's advocacy creates a supportive community that reduces isolation and advances research toward a cure, making tomorrow better for those with Type 1 diabetes.</li>            <li>A Jacksonville family transformed their son's Type 1 diabetes diagnosis into Pablo's Pack T1D, an inspiring initiative that builds community and supports research through fundraising walks.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news highlights a critical model of patient and family-led advocacy that directly addresses the daily realities of managing a chronic condition like Type 1 diabetes. For the millions of individuals and families affected globally, stories like this demonstrate that a diagnosis does not have to be faced in isolation. The work of Pablo's Pack T1D provides tangible resources and emotional support, which are essential for navigating complex care routines and the associated psychological burden. Furthermore, their focus on driving participation in established fundraising events like the Breakthrough T1D Walk channels community energy directly toward accelerating research for better treatments and a potential cure. This grassroots-to-global approach empowers affected families, strengthens support networks, and directly contributes to the scientific and systemic advancements needed to ultimately reduce the disease's lifelong impact.</p>        <h2>Summary</h2>        <p><p>In Jacksonville, Florida, a family has transformed their personal experience with Type 1 diabetes into a powerful force for advocacy and community support through their initiative, Pablo\u2019s Pack T1D. When Andrea and her husband Pablo received the life-changing diagnosis that their son had Type 1 diabetes, they channeled their initial uncertainty into a shared mission. Their platform, accessible via Pablo\u2019s Pack T1D, serves as a vital resource hub, sharing the family's firsthand experiences with daily glucose monitoring, necessary lifestyle adjustments, and the emotional resilience required to manage this chronic condition. By providing these resources, they aim to foster a supportive community for other families navigating similar challenges, ensuring no one feels alone on this journey.</p><p>The family's advocacy extends beyond their digital platform through active participation in the Breakthrough T1D Walk, a national fundraising initiative. This event is a cornerstone of their efforts, bringing together families, advocates, and supporters to advance critical research and improve the lives of those living with Type 1 diabetes. As Andrea poignantly stated, their son's diagnosis 'gave us a purpose,' driving them to connect with others and work toward a better future. The walk supports efforts to accelerate scientific breakthroughs, improve access to care, and advance toward a cure, while also creating invaluable opportunities for peer connection and shared experience.</p><p>Through storytelling and community engagement, Pablo\u2019s Pack T1D continues to raise awareness and encourage participation in initiatives that support ongoing research and advocacy. It is important to note that Pablo\u2019s Pack T1D is a community-driven initiative, not a registered nonprofit; donations associated with their participation are directed to Breakthrough T1D, a registered 501(c)(3) organization funding research, advocacy, and education programs. This ensures contributions directly support the mission to improve lives and find a cure. Their story, detailed at their website, exemplifies how personal adversity can be harnessed to build community, provide practical support, and fuel the collective push for medical progress in the fight against Type 1 diabetes.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/952900c048c66725e4245b57287e8e0e.30946.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/952900c048c66725e4245b57287e8e0e.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.noticiasnewswire.com/'>Noticias Newswire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/noticias-newswire/en//952900c048c66725e4245b57287e8e0e'>Jacksonville Family Turns Son's T1D Diagnosis Into Advocacy Powerhouse.</a></p></div>        </article>    ", "published": "2026-04-15T17:34:36+00:00", "audio_release": "https://cdn.newsramp.net/audio/952900c048c66725e4245b57287e8e0e.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/952900c048c66725e4245b57287e8e0e.webp", "enclosure": "https://cdn.newsramp.app/noticias-newswire/newsimage/952900c048c66725e4245b57287e8e0e.jpg", "site_handle": "noticias-newswire", "seo_description": "A Jacksonville family transforms their son's Type 1 diabetes diagnosis into Pablo's Pack T1D, an advocacy initiative providing resources & driving support for the Breakthrough T1D Walk to fund research.", "newsramp_curated": "https://newsramp.com/curated-news/jacksonville-family-turns-son-s-t1d-diagnosis-into-advocacy-powerhouse/952900c048c66725e4245b57287e8e0e"}, {"feed_item_id": 30941, "prhash_id": "59a10dde8494de46441798c5e283d06d", "headline": "Earth Science Tech Builds Value Through Healthcare Acquisitions", "content": "        <article>        <h1>Earth Science Tech Builds Value Through Healthcare Acquisitions</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-7.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Earth Science Tech Builds Value Through Healthcare Acquisitions'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Earth Science Tech's strategic acquisitions in compounding pharmacies and telehealth platforms create a diversified healthcare portfolio that enhances shareholder value through scalable growth.</li>            <li>Earth Science Tech operates as a holding company that acquires and manages healthcare businesses, including compounding pharmacies and telehealth platforms, to optimize operations and drive long-term value.</li>            <li>Earth Science Tech's subsidiaries provide personalized wellness programs and prescription cost assistance through its nonprofit foundation, improving healthcare access for diverse communities across the United States.</li>            <li>Earth Science Tech's portfolio includes compounding pharmacies serving over 20 states and a telemedicine platform offering doctor-verified treatments through innovative healthcare delivery models.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it highlights Earth Science Tech's strategic expansion in the growing healthcare and telemedicine sectors, which have seen increased demand and innovation. For investors, the company's focus on capital discipline and long-term value creation across compounding pharmacies, telehealth platforms, and community health services presents a diversified approach to tapping into healthcare trends. The emphasis on personalized wellness programs and prescription cost assistance through its foundation also addresses broader societal needs for accessible healthcare. As healthcare continues to evolve with technology and personalized medicine, Earth Science Tech's portfolio could position it for sustainable growth, making it relevant for those monitoring investment opportunities in health-focused holding companies.</p>        <h2>Summary</h2>        <p><p>Earth Science Tech (OTC: ETST), a strategic holding company, has been featured in a recent article highlighting its disciplined approach to building value through acquisitions and active management of businesses. The company prioritizes capital discipline, execution, and long-term value creation across its diverse portfolio, focusing on scaling sustainable businesses to increase shareholder value. Key players include Earth Science Tech's leadership team and its network of subsidiaries, which form the core of its operational strategy.</p><p>The company's portfolio includes several healthcare-focused subsidiaries: Mister Meds LLC, a compounding pharmacy offering personalized wellness plans; RxCompoundStore.com LLC, another compounding pharmacy authorized in over 20 states and Puerto Rico; Peaks Curative LLC, a telemedicine referral platform; Las Villas Health Care Inc., serving Spanish-speaking communities with personalized wellness programs; DOConsultations LLC, a telehealth platform supporting direct delivery through partner pharmacies; and Earth Science Foundation Inc., the company's charitable arm providing prescription cost assistance. These operations demonstrate Earth Science Tech's commitment to the healthcare sector through compounding pharmaceuticals, telemedicine, and real estate development.</p><p>The article was published by NetworkNewsWire (NNW), a specialized communications platform within the Dynamic Brand Portfolio at IBN that provides financial news distribution and corporate communications solutions. NNW offers services including wire solutions via InvestorWire, article syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications. Readers can access the full article through the provided hyperlink and stay updated via the company's newsroom. This coverage reflects Earth Science Tech's efforts to gain recognition in the investment community while showcasing its multi-faceted approach to value creation in the competitive healthcare market.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/59a10dde8494de46441798c5e283d06d.30941.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/59a10dde8494de46441798c5e283d06d.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//59a10dde8494de46441798c5e283d06d'>Earth Science Tech Builds Value Through Healthcare Acquisitions.</a></p></div>        </article>    ", "published": "2026-04-15T16:53:55+00:00", "audio_release": "https://cdn.newsramp.net/audio/59a10dde8494de46441798c5e283d06d.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/59a10dde8494de46441798c5e283d06d.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-7.jpg", "site_handle": "ibn", "seo_description": "Earth Science Tech (ETST) featured for strategic healthcare acquisitions, including compounding pharmacies and telemedicine platforms. Learn about its value creation approach and subsidiaries like Mister Meds and RxCompoundStore.", "newsramp_curated": "https://newsramp.com/curated-news/earth-science-tech-builds-value-through-healthcare-acquisitions/59a10dde8494de46441798c5e283d06d"}, {"feed_item_id": 30935, "prhash_id": "f2b67e7087d6ddee76cb962a6ec4b200", "headline": "Earth Science Tech Builds Healthcare Empire Through Strategic Acquisitions", "content": "        <article>        <h1>Earth Science Tech Builds Healthcare Empire Through Strategic Acquisitions</h1>        <img src='https://cdn.newsramp.app/banners/business-corporate-4.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Earth Science Tech Builds Healthcare Empire Through Strategic Acquisitions'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Earth Science Tech's strategic acquisitions and capital discipline create a diversified healthcare portfolio that can deliver sustainable growth and increased shareholder value.</li>            <li>Earth Science Tech operates as a holding company managing subsidiaries in compounding pharmacies, telemedicine platforms, and healthcare services to optimize operations and build long-term value.</li>            <li>Through its subsidiaries and nonprofit foundation, Earth Science Tech provides personalized healthcare, telehealth access, and prescription cost assistance, improving wellness for diverse communities across the United States.</li>            <li>Earth Science Tech's portfolio includes compounding pharmacies serving over 20 states, Spanish-language healthcare services, and a charitable foundation helping with prescription costs.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it highlights Earth Science Tech's expansion in the growing telehealth and personalized medicine sectors, which are increasingly important as healthcare shifts toward remote and customized solutions. For investors, the company's disciplined acquisition strategy and diversified portfolio\u2014spanning compounding pharmacies, telemedicine platforms, and even real estate\u2014suggest potential for sustainable growth and value creation. For consumers, especially those in underserved communities like Spanish-speaking populations, the company's services offer improved access to personalized wellness plans and prescription assistance. The involvement of platforms like InvestorWire ensures broader market awareness, which could influence investment decisions and industry trends in healthcare innovation.</p>        <h2>Summary</h2>        <p><p>Earth Science Tech (OTC: ETST), a strategic holding company, has been featured in a recent article highlighting its disciplined approach to building value through acquisitions and active management of healthcare businesses. The company emphasizes capital discipline, execution, and long-term value creation across its diverse portfolio, which includes multiple subsidiaries focused on compounding pharmaceuticals, telemedicine, and personalized wellness. Key players in this ecosystem include Mister Meds LLC, a compounding pharmacy delivering personalized wellness plans across the USA; RxCompoundStore.com LLC, another compounding pharmacy authorized in over 20 states and Puerto Rico; Peaks Curative LLC, a telemedicine referral platform; Las Villas Health Care Inc., serving Spanish-speaking communities; DOConsultations LLC, a telehealth platform; and Earth Science Foundation Inc., the company's charitable arm providing prescription cost assistance.</p><p>The article, available through the InvestorWire platform, details how Earth Science Tech operates as a strategic holding company focused on operational optimization and management of its wholly owned and majority-owned subsidiaries. Beyond the healthcare-focused entities, the company also maintains interests in real estate development through Avenvi, LLC and an 80% stake in MagneChef, demonstrating a diversified approach to value creation. The coverage was distributed via InvestorWire, which is part of the Dynamic Brand Portfolio at IBN, leveraging advanced wire-grade press release syndication, editorial distribution to over 5,000 outlets, and enhanced social media distribution to reach investors and the general public effectively.</p><p>For investors seeking the latest updates, the company maintains a dedicated newsroom accessible through the provided link. This comprehensive approach to corporate communications ensures that Earth Science Tech's strategic initiatives in compounding pharmaceuticals, telemedicine, and beyond receive appropriate market visibility. The company's focus on scaling sustainable businesses that increase shareholder value while addressing specific healthcare needs\u2014from personalized wellness plans to financial assistance for prescriptions\u2014positions it uniquely in the evolving healthcare landscape.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/f2b67e7087d6ddee76cb962a6ec4b200.30935.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/f2b67e7087d6ddee76cb962a6ec4b200.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//f2b67e7087d6ddee76cb962a6ec4b200'>Earth Science Tech Builds Healthcare Empire Through Strategic Acquisitions.</a></p></div>        </article>    ", "published": "2026-04-15T16:26:27+00:00", "audio_release": "https://cdn.newsramp.net/audio/f2b67e7087d6ddee76cb962a6ec4b200.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/f2b67e7087d6ddee76cb962a6ec4b200.webp", "enclosure": "https://cdn.newsramp.app/banners/business-corporate-4.jpg", "site_handle": "ibn", "seo_description": "Earth Science Tech (ETST) expands its healthcare portfolio with strategic acquisitions in compounding pharmacies and telemedicine, focusing on personalized wellness and shareholder value creation.", "newsramp_curated": "https://newsramp.com/curated-news/earth-science-tech-builds-healthcare-empire-through-strategic-acquisitions/f2b67e7087d6ddee76cb962a6ec4b200"}, {"feed_item_id": 30933, "prhash_id": "69291ab3509dbbeb4769519576a4aa18", "headline": "Kairos Pharma Wins 2026 Pinnacle Award for Cancer Drug Resistance Innovation", "content": "        <article>        <h1>Kairos Pharma Wins 2026 Pinnacle Award for Cancer Drug Resistance Innovation</h1>        <img src='https://cdn.newsramp.app/banners/awards-6.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Kairos Pharma Wins 2026 Pinnacle Award for Cancer Drug Resistance Innovation'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Kairos Pharma's Emerald award recognition at the 2026 Pinnacle Awards signals a competitive edge in developing resistance-modulating cancer treatments that could enhance therapy effectiveness.</li>            <li>Kairos Pharma's ENV-105 targets the CD105 protein to inhibit tumor resistance pathways, using structural biology to restore standard therapy effectiveness in clinical trials for multiple cancers.</li>            <li>Kairos Pharma's innovative approach to overcoming cancer drug resistance aims to improve patient outcomes and durability of response, making tomorrow better for those battling the disease.</li>            <li>Kairos Pharma's lead candidate ENV-105 is an antibody targeting CD105, a protein identified as a key driver of cancer relapse and resistance to standard therapies.</li>        </ul>        <h2>Why it Matters</h2>        <p>This development matters because cancer drug resistance remains one of the most significant challenges in oncology, often leading to treatment failure and disease progression. When cancer cells develop resistance to standard therapies, patients face limited options and poorer outcomes. Kairos Pharma's approach to modulating resistance pathways represents a promising direction in cancer treatment that could extend the effectiveness of existing therapies and improve patient survival rates. The company's focus on combination approaches addresses a critical need in cancer care, potentially benefiting millions of patients worldwide who face treatment-resistant cancers. The recognition at the prestigious Pinnacle Awards validates the scientific merit of this approach and signals progress toward more durable cancer treatments.</p>        <h2>Summary</h2>        <p><p>Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has been honored as an Emerald honoree at the prestigious 2026 Pinnacle Awards for Healthcare. This recognition celebrates the company's innovative strategy to combat cancer drug resistance, a major challenge in oncology treatment. The company's approach focuses on resistance-modulating treatments, with its lead candidate ENV-105 (carotuximab) designed to inhibit tumor resistance pathways and enhance the effectiveness of existing therapies. Kairos Pharma is advancing combination approaches aimed at improving durability of response across multiple cancer indications, positioning itself at the forefront of oncology therapeutics.</p><p>Based in Los Angeles, California, Kairos Pharma utilizes structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105\u2014a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. It's important to note that as of the press release date, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.</p><p>The press release was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides advanced wire-grade press release syndication for private and public companies and the investment community, offering access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement for maximum impact, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. For more information about Kairos Pharma, investors can visit the company's newsroom at https://ibn.fm/KAPA or view the full press release at https://ibn.fm/ghPJC.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/69291ab3509dbbeb4769519576a4aa18.30933.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/69291ab3509dbbeb4769519576a4aa18.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//69291ab3509dbbeb4769519576a4aa18'>Kairos Pharma Wins 2026 Pinnacle Award for Cancer Drug Resistance Innovation.</a></p></div>        </article>    ", "published": "2026-04-15T15:59:35+00:00", "audio_release": "https://cdn.newsramp.net/audio/69291ab3509dbbeb4769519576a4aa18.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/69291ab3509dbbeb4769519576a4aa18.webp", "enclosure": "https://cdn.newsramp.app/banners/awards-6.jpg", "site_handle": "ibn", "seo_description": "Kairos Pharma wins 2026 Pinnacle Award for innovative cancer drug resistance treatments. Learn about ENV-105 clinical trials and their approach to overcoming treatment resistance in oncology.", "newsramp_curated": "https://newsramp.com/curated-news/kairos-pharma-wins-2026-pinnacle-award-for-cancer-drug-resistance-innovation/69291ab3509dbbeb4769519576a4aa18"}, {"feed_item_id": 30927, "prhash_id": "d794b4f99420806b0bb7ba29bb744d38", "headline": "Polyrizon Secures $3.5M Funding for Nasal Shield Biotech Innovation", "content": "        <article>        <h1>Polyrizon Secures $3.5M Funding for Nasal Shield Biotech Innovation</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-3.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Polyrizon Secures $3.5M Funding for Nasal Shield Biotech Innovation'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Polyrizon secured $3.5 million in funding, providing capital to advance its intranasal protective technology and potentially gain an edge in biotech innovation.</li>            <li>Polyrizon raised $3.5 million through a direct offering and private placement, selling units at $9.00 each to fund working capital and corporate operations.</li>            <li>Polyrizon's nasal spray technology creates a protective barrier against viruses and allergens, aiming to improve public health and reduce disease transmission.</li>            <li>Polyrizon is developing a nasal hydrogel that acts as a biological mask, using natural building blocks to trap viruses before they infect tissue.</li>        </ul>        <h2>Why it Matters</h2>        <p>This development matters because Polyrizon's intranasal protective technology represents a potentially transformative approach to respiratory health protection. In a world increasingly concerned about viral transmission and airborne allergens, a non-invasive nasal barrier could offer significant advantages over traditional masks and medications. The funding enables continued research and development of what essentially functions as a 'biological mask' - technology that could provide continuous protection without the discomfort and limitations of physical face coverings. For investors, this represents an opportunity in the growing biotech sector focused on preventive healthcare solutions. For the general public, successful development could lead to more convenient, effective protection against respiratory illnesses and allergens, potentially reducing healthcare costs and improving quality of life for millions who suffer from seasonal allergies or are at risk of viral infections. The company's additional work on drug delivery through nasal sprays could also revolutionize how medications are administered, making treatments more targeted and efficient.</p>        <h2>Summary</h2>        <p><p>Polyrizon Ltd. (NASDAQ: PLRZ), a pre-clinical-stage biotechnology company, has successfully secured approximately $3.5 million in gross proceeds through a registered direct offering and concurrent private placement with a single institutional investor. The financial transactions involved the sale of 388,888 units or pre-funded units at a combined price of $9.00 per unit, which included ordinary shares or pre-funded warrants and common warrants, with additional warrants issued in the private placement. Aegis Capital Corp. served as the exclusive placement agent for these deals, and the company intends to allocate the proceeds toward working capital and general corporate purposes, bolstering its operational capabilities during this critical development phase.</p><p>At the core of Polyrizon's innovative approach is its proprietary Capture and Contain\u2122 (C&C) hydrogel technology, which forms the basis of its intranasal protective solutions. This technology, delivered via nasal sprays, creates a thin hydrogel-based shield containment barrier in the nasal cavity, designed to act as a 'biological mask' by preventing viruses and allergens from contacting nasal epithelial tissue. The company is further advancing its C&C hydrogel technology to enhance bioadhesion and prolonged retention for intranasal drug delivery, while also developing an earlier-stage pre-clinical technology called Trap and Target\u2122 (T&T) focused on nasal delivery of active pharmaceutical ingredients (APIs). For more detailed information, readers can view the full press release through the provided link.</p><p>The news was disseminated by TechMediaWire (TMW), a specialized communications platform within the Dynamic Brand Portfolio @ IBN that focuses on technology-driven companies. TMW provides comprehensive services including access to wire solutions via InvestorWire, article and editorial syndication to over 5,000 outlets, enhanced press release distribution, social media distribution through IBN's network, and tailored corporate communications solutions. This platform helps companies like Polyrizon reach a wide audience of investors, influencers, consumers, and journalists, ensuring maximum visibility in today's crowded information landscape. For those interested in staying updated on technology news, TMW offers SMS alerts by texting 'TECH' to 888-902-4192 (U.S. Mobile Phones Only).</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/d794b4f99420806b0bb7ba29bb744d38.30927.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/d794b4f99420806b0bb7ba29bb744d38.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//d794b4f99420806b0bb7ba29bb744d38'>Polyrizon Secures $3.5M Funding for Nasal Shield Biotech Innovation.</a></p></div>        </article>    ", "published": "2026-04-15T14:48:22+00:00", "audio_release": "https://cdn.newsramp.net/audio/d794b4f99420806b0bb7ba29bb744d38.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/d794b4f99420806b0bb7ba29bb744d38.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-3.jpg", "site_handle": "ibn", "seo_description": "Polyrizon raises $3.5M for nasal hydrogel technology that creates a biological mask barrier against viruses and allergens. Learn about their innovative Capture and Contain\u2122 platform.", "newsramp_curated": "https://newsramp.com/curated-news/polyrizon-secures-3-5m-funding-for-nasal-shield-biotech-innovation/d794b4f99420806b0bb7ba29bb744d38"}, {"feed_item_id": 30925, "prhash_id": "b53c1abe1d870e97785c31aec2c6960a", "headline": "Canadian Scientists Discover Brain Cells Fuel Deadly Glioblastoma Tumors", "content": "        <article>        <h1>Canadian Scientists Discover Brain Cells Fuel Deadly Glioblastoma Tumors</h1>        <img src='https://cdn.newsramp.app/banners/science-7.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Canadian Scientists Discover Brain Cells Fuel Deadly Glioblastoma Tumors'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>CNS Pharmaceuticals Inc. gains a competitive edge by targeting newly discovered glioblastoma-supporting cells, potentially accelerating effective treatment development.</li>            <li>Canadian scientists found that passive brain cells actively fuel glioblastoma growth through signaling, revealing a new therapeutic target for companies like CNS Pharmaceuticals Inc.</li>            <li>This discovery offers hope for better glioblastoma treatments, potentially improving survival rates and quality of life for patients worldwide.</li>            <li>Brain cells once thought passive secretly fuel deadly cancer growth, a surprising finding that could revolutionize glioblastoma treatment approaches.</li>        </ul>        <h2>Why it Matters</h2>        <p>This discovery fundamentally changes our understanding of glioblastoma biology by revealing that non-cancerous brain cells actively contribute to tumor growth rather than just providing passive support. For patients facing this aggressive brain cancer with limited treatment options, this finding opens new therapeutic avenues that could target these supportive cells alongside cancer cells themselves. The research could lead to more effective combination therapies and potentially improve survival rates for a disease that currently has a devastating prognosis. For investors and the medical community, it highlights the importance of continued research investment and the potential for companies like CNS Pharmaceuticals to develop novel treatments based on these biological insights.</p>        <h2>Summary</h2>        <p><p>Canadian scientists have made an unexpected finding about glioblastoma, one of the deadliest and hardest-to-treat forms of brain cancer, revealing that cells previously considered passive support structures in healthy brain tissue actually actively fuel tumor growth through signaling that boosts cancer cell function. This discovery challenges long-held assumptions about brain cancer biology and opens new avenues for therapeutic intervention against a disease notorious for its aggressive nature and limited treatment options.</p><p>The rush to develop effective therapies against glioblastoma is gaining momentum, with entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) working tirelessly to bring to market new treatments that move the dial in the fight against this deadly type of brain cancer. As more insights about what drives tumor progression emerge, companies like CNS Pharmaceuticals are positioned to translate these scientific breakthroughs into clinical applications, potentially offering hope where traditional approaches have fallen short.</p><p>This news is presented by TinyGems, a specialized communications platform within the Dynamic Brand Portfolio at IBN that focuses on innovative small-cap and mid-cap companies with bright futures and huge potential. Through services like article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution via IBN to millions of followers, TinyGems helps companies reach a wide audience of investors, influencers, and the general public. The platform's comprehensive corporate communications solutions ensure that important developments in fields like oncology research receive the visibility they deserve, connecting scientific progress with investment opportunities and public awareness.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/b53c1abe1d870e97785c31aec2c6960a.30925.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/b53c1abe1d870e97785c31aec2c6960a.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//b53c1abe1d870e97785c31aec2c6960a'>Canadian Scientists Discover Brain Cells Fuel Deadly Glioblastoma Tumors.</a></p></div>        </article>    ", "published": "2026-04-15T14:05:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/b53c1abe1d870e97785c31aec2c6960a.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/b53c1abe1d870e97785c31aec2c6960a.webp", "enclosure": "https://cdn.newsramp.app/banners/science-7.jpg", "site_handle": "ibn", "seo_description": "Canadian scientists discover brain cells actively fuel glioblastoma growth, challenging cancer biology. CNS Pharmaceuticals develops new treatments as TinyGems reports on this breakthrough finding.", "newsramp_curated": "https://newsramp.com/curated-news/canadian-scientists-discover-brain-cells-fuel-deadly-glioblastoma-tumors/b53c1abe1d870e97785c31aec2c6960a"}, {"feed_item_id": 30922, "prhash_id": "768e527ea006665133e893e3058a5306", "headline": "Tonix Pharma's TONMYA Study Shows Faster Absorption for Fibromyalgia Treatment", "content": "        <article>        <h1>Tonix Pharma's TONMYA Study Shows Faster Absorption for Fibromyalgia Treatment</h1>        <img src='https://cdn.newsramp.app/banners/technology-4.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Tonix Pharma's TONMYA Study Shows Faster Absorption for Fibromyalgia Treatment'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Tonix Pharmaceuticals' TONMYA offers faster absorption and higher bioavailability than existing treatments, potentially capturing market share in fibromyalgia care.</li>            <li>A peer-reviewed study of 60 volunteers shows TNX-102 SL achieves faster absorption and higher bioavailability than oral cyclobenzaprine for bedtime dosing.</li>            <li>This new formulation could improve sleep and reduce pain for fibromyalgia patients, enhancing daily functioning and quality of life.</li>            <li>Tonix's sublingual tablet is the first new fibromyalgia treatment in 15 years, using faster absorption to target nonrestorative sleep.</li>        </ul>        <h2>Why it Matters</h2>        <p>This development matters because fibromyalgia affects millions worldwide, often causing chronic pain, fatigue, and sleep disturbances that significantly impair quality of life. The condition has seen limited treatment advances in recent years, leaving many patients with inadequate options. TONMYA's sublingual formulation offering faster absorption and improved bioavailability could provide more effective symptom management, particularly for nonrestorative sleep\u2014a core fibromyalgia complaint. Beyond immediate patient benefits, Tonix's broader pipeline targeting CNS disorders and immunological conditions addresses multiple areas of high unmet medical need. The company's research into TONMYA for depression and stress disorders, along with programs for rare diseases like Prader-Willi syndrome and transplant rejection prevention, demonstrates a comprehensive approach to challenging medical conditions. For investors and the healthcare community, Tonix represents innovation in biotechnology with potential market impact across several therapeutic areas.</p>        <h2>Summary</h2>        <p><p>Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a commercial-stage biotechnology company, has announced a significant milestone with the publication of a peer-reviewed study in <em>Clinical Pharmacology in Drug Development</em>. The research details the steady-state pharmacokinetic properties of TNX-102 SL, the sublingual formulation of cyclobenzaprine HCl marketed as TONMYA(R). Conducted with 60 healthy volunteers, the study demonstrated that this sublingual formulation achieves faster absorption, earlier peak plasma concentration, and higher dose-normalized bioavailability compared to oral extended-release cyclobenzaprine. These findings support TONMYA's use for long-term bedtime dosing to target nonrestorative sleep in fibromyalgia patients, potentially reducing pain and improving related symptoms. This development is particularly noteworthy as TONMYA represents the first new treatment for fibromyalgia in over 15 years, addressing a condition with high unmet medical need.</p><p>Tonix Pharmaceuticals is a fully-integrated company focused on central nervous system (CNS) and immunology treatments. Beyond TONMYA, their commercial infrastructure supports marketed acute migraine products including Zembrace(R) SymTouch(R) and Tosymra(R). The company is actively exploring TONMYA's potential in other areas through Phase 2 clinical trials for major depressive disorder and acute stress disorder. Additionally, Tonix's pipeline includes TNX-2900, which is Phase 2 ready for treating Prader-Willi syndrome, and immunology programs such as monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. It's important to note that while promising, these product development candidates remain investigational new drugs or biologics whose efficacy and safety have not been established for any indication.</p><p>This news was disseminated through TinyGems, a specialized communications platform within the Dynamic Brand Portfolio @ IBN that focuses on innovative small-cap and mid-cap companies. TinyGems provides comprehensive corporate communications solutions including access to wire solutions via InvestorWire, article and editorial syndication to over 5,000 outlets, enhanced press release services, and social media distribution through IBN's extensive network. The platform aims to deliver unparalleled recognition and brand awareness for companies seeking to reach investors, influencers, consumers, and journalists. For those interested in following developments from companies like Tonix Pharmaceuticals, TinyGems offers SMS alerts by texting 'Gems' to 888-902-4192 (U.S. mobile phones only). Additional information and disclaimers are available on the TinyGems website.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/768e527ea006665133e893e3058a5306.30922.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/768e527ea006665133e893e3058a5306.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//768e527ea006665133e893e3058a5306'>Tonix Pharma's TONMYA Study Shows Faster Absorption for Fibromyalgia Treatment.</a></p></div>        </article>    ", "published": "2026-04-15T14:00:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/768e527ea006665133e893e3058a5306.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/768e527ea006665133e893e3058a5306.webp", "enclosure": "https://cdn.newsramp.app/banners/technology-4.jpg", "site_handle": "ibn", "seo_description": "Tonix Pharmaceuticals publishes study showing TONMYA's faster absorption for fibromyalgia treatment. First new fibromyalgia drug in 15 years with potential for improved sleep and pain management.", "newsramp_curated": "https://newsramp.com/curated-news/tonix-pharma-s-tonmya-study-shows-faster-absorption-for-fibromyalgia-treatment/768e527ea006665133e893e3058a5306"}, {"feed_item_id": 30939, "prhash_id": "28fcaeb2a4cbb125029c547e650d9f26", "headline": "Compact Proton Therapy Breakthrough Makes Cancer Treatment More Accessible", "content": "        <article>        <h1>Compact Proton Therapy Breakthrough Makes Cancer Treatment More Accessible</h1>        <img src='https://cdn.newsramp.app/banners/technology-4.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Compact Proton Therapy Breakthrough Makes Cancer Treatment More Accessible'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Liora Technologies' compact LiGHT System offers a competitive edge by making proton therapy more accessible and affordable for cancer treatment.</li>            <li>The LiGHT System uses compact, precise technology to deliver proton therapy, targeting tumors while minimizing damage to surrounding healthy tissue.</li>            <li>This advancement makes proton therapy more accessible, improving cancer treatment outcomes and quality of life for patients worldwide.</li>            <li>Proton therapy, once limited by size and cost, is becoming more viable through innovative compact systems like Liora's LiGHT.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it represents a tangible step toward democratizing advanced cancer care. Proton therapy offers significant advantages over traditional radiation by minimizing damage to healthy tissue surrounding tumors, which can reduce side effects and improve recovery for patients. Historically, its high cost and massive infrastructure requirements limited it to major medical centers, creating geographic and economic disparities in access. By shrinking the equipment's footprint and cost, innovations like Liora Technologies' LiGHT System could bring this precision treatment to more community hospitals and cancer centers worldwide. This expansion means potentially better outcomes and quality of life for a wider range of cancer patients, particularly those with tumors near critical organs or in pediatric cases where preserving healthy tissue is paramount. It also signals progress in making expensive medical technologies more sustainable and scalable, which is crucial for addressing global healthcare challenges.</p>        <h2>Summary</h2>        <p><p>Proton therapy, a specialized cancer treatment that uses precision-guided radiation beams to target tumors while sparing healthy tissue, has long been inaccessible to many patients due to the enormous size and prohibitive cost of traditional equipment. This landscape is now shifting as technological advancements are making the equipment more compact and affordable, opening up this potentially life-saving treatment to a broader patient population. Key players in this movement include academic institutions like Stanford and innovative companies such as Liora Technologies, a UK-based subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), which is pioneering a new era of accessible proton therapy.</p><p>Liora Technologies is at the forefront of this revolution with its Linac for Image Guided Hadron Therapy ('LiGHT') System, designed to be a compact, precise, and more accessible proton therapy solution. This development is part of a broader effort to democratize advanced cancer care, moving it from a niche, resource-intensive option to a viable treatment for more patients who could benefit from its precision. The news highlights the critical role of such innovations in overcoming historical barriers to advanced medical treatments, making them available where they were previously out of reach due to logistical and financial constraints.</p><p>The coverage of this advancement is provided by TinyGems, a specialized communications platform within the Dynamic Brand Portfolio focused on innovative small-cap and mid-cap companies. For those interested in deeper insights, the full article offers more details on how this compact proton therapy delivery helps make the treatment more accessible for cancer patients. This story underscores a significant trend in medical technology where miniaturization and cost reduction can directly translate to improved patient outcomes and expanded access to cutting-edge therapies, marking a hopeful development in the ongoing fight against cancer.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/28fcaeb2a4cbb125029c547e650d9f26.30939.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/28fcaeb2a4cbb125029c547e650d9f26.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//28fcaeb2a4cbb125029c547e650d9f26'>Compact Proton Therapy Breakthrough Makes Cancer Treatment More Accessible.</a></p></div>        </article>    ", "published": "2026-04-15T13:50:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/28fcaeb2a4cbb125029c547e650d9f26.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/28fcaeb2a4cbb125029c547e650d9f26.webp", "enclosure": "https://cdn.newsramp.app/banners/technology-4.jpg", "site_handle": "ibn", "seo_description": "Liora Technologies' compact proton therapy system aims to make precision cancer treatment more accessible by reducing size and cost, expanding options for patients.", "newsramp_curated": "https://newsramp.com/curated-news/compact-proton-therapy-breakthrough-makes-cancer-treatment-more-accessible/28fcaeb2a4cbb125029c547e650d9f26"}, {"feed_item_id": 30917, "prhash_id": "7f80d153dc88a7da38f2fb99772e5fc6", "headline": "HeartBeam Launches Public Offering to Fuel Cardiac Tech Innovation", "content": "        <article>        <h1>HeartBeam Launches Public Offering to Fuel Cardiac Tech Innovation</h1>        <img src='https://cdn.newsramp.app/banners/frontier-tech-4.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='HeartBeam Launches Public Offering to Fuel Cardiac Tech Innovation'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>HeartBeam's public offering provides investment opportunities to capitalize on its FDA-cleared 3D ECG technology for portable cardiac monitoring.</li>            <li>HeartBeam will use offering proceeds to commercialize its 12-lead ECG system, develop extended-wear patches, enhance AI, and support working capital through Titan Partners.</li>            <li>HeartBeam's technology enables early cardiac condition detection outside medical facilities, improving patient outcomes and accessibility to heart health management.</li>            <li>HeartBeam creates the first cable-free 3D ECG device, synthesizing signals into 12-lead readings for portable heart monitoring with over 20 patents.</li>        </ul>        <h2>Why it Matters</h2>        <p>This development matters because HeartBeam's technology represents a significant advancement in cardiac care accessibility and early detection. Cardiovascular disease remains a leading cause of death globally, and traditional ECG monitoring typically requires hospital visits and cumbersome equipment. HeartBeam's portable, cable-free 3D ECG system could enable remote monitoring and earlier intervention for heart conditions, potentially saving lives by detecting problems before they become emergencies. For patients, this means more convenient, continuous cardiac monitoring without disrupting daily life. For healthcare systems, it offers potential cost savings through reduced hospitalizations and more efficient resource allocation. The public offering provides the capital needed to bring this innovative technology to market faster, accelerating its potential to transform how cardiac conditions are detected and managed worldwide.</p>        <h2>Summary</h2>        <p><p>HeartBeam (NASDAQ: BEAT), a pioneering medical technology company, has announced it is commencing an underwritten public offering of its common stock, with the final size and terms dependent on market conditions. The company plans to use the net proceeds to advance the commercialization of its groundbreaking FDA-cleared 12-lead synthesized ECG system, further develop its extended-wear patch and heart attack detection initiatives, enhance its AI capabilities, and support general corporate purposes. Titan Partners, a division of American Capital Partners, is acting as the sole bookrunner for this significant financial move, which aims to fuel the company's ambitious growth and innovation trajectory in the cardiac care sector.</p><p>HeartBeam is dedicated to transforming the detection and monitoring of critical cardiac conditions through its revolutionary technology. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence to physicians. The technology, which received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025, enables physicians to identify cardiac health trends and acute conditions outside traditional medical facilities, potentially redefining cardiac health management. The company holds over 20 issued patents related to this transformative technology.</p><p>The news release was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN, which focuses on the latest developments in biotechnology, biomedical sciences, and life sciences. BioMedWire provides comprehensive distribution services including access to wire solutions, article syndication to over 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more detailed information, readers can view the full press release or visit the company's newsroom for the latest updates relating to BEAT, ensuring they stay informed about this innovative company's progress and market developments.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/7f80d153dc88a7da38f2fb99772e5fc6.30917.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/7f80d153dc88a7da38f2fb99772e5fc6.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//7f80d153dc88a7da38f2fb99772e5fc6'>HeartBeam Launches Public Offering to Fuel Cardiac Tech Innovation.</a></p></div>        </article>    ", "published": "2026-04-15T13:20:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/7f80d153dc88a7da38f2fb99772e5fc6.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/7f80d153dc88a7da38f2fb99772e5fc6.webp", "enclosure": "https://cdn.newsramp.app/banners/frontier-tech-4.jpg", "site_handle": "ibn", "seo_description": "HeartBeam announces public offering to fund FDA-cleared 3D ECG technology development. Medical tech company aims to revolutionize cardiac care with portable heart monitoring devices.", "newsramp_curated": "https://newsramp.com/curated-news/heartbeam-launches-public-offering-to-fuel-cardiac-tech-innovation/7f80d153dc88a7da38f2fb99772e5fc6"}, {"feed_item_id": 30936, "prhash_id": "3585bbbde487ee0d4aaca5bc5f07b256", "headline": "Soligenix Gains Analytical Validation as Pipeline Progress Drives Forward Outlook", "content": "        <article>        <h1>Soligenix Gains Analytical Validation as Pipeline Progress Drives Forward Outlook</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-6.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Soligenix Gains Analytical Validation as Pipeline Progress Drives Forward Outlook'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Soligenix's strong interim FLASH2 data and upcoming catalysts position investors for potential gains as the company advances its phase 3 trial.</li>            <li>Zacks Research analyzed Soligenix's pipeline progress, including phase 3 FLASH2 trial interim data trends and upcoming milestones, to assess valuation potential.</li>            <li>Soligenix's HyBryte treatment for cutaneous T-cell lymphoma could improve patient outcomes, representing meaningful progress in cancer therapy development.</li>            <li>A Zacks analysis highlights Soligenix's promising FLASH2 study data and pipeline depth, offering insight into this emerging biotech company's strategy.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because independent research validation from respected firms like Zacks can significantly influence investor confidence and market perception of emerging biotech companies. For patients with cutaneous T-cell lymphoma, the progress of HyBryte\u2122 through phase 3 trials represents potential new treatment options. For investors, the detailed analysis provides crucial insights into valuation drivers and upcoming catalysts that could impact stock performance. In the competitive biotech sector, such third-party validation helps distinguish promising companies from the crowded field, potentially affecting funding opportunities and partnership discussions.</p>        <h2>Summary</h2>        <p><p>A recent analysis from Zacks Small-Cap Research provides a comprehensive outlook on Soligenix (NASDAQ: SNGX), highlighting the company's promising pipeline and upcoming milestones that position it for a potentially eventful period ahead. The report emphasizes the strength of interim data trends from the phase 3 FLASH2 clinical trial evaluating HyBryte\u2122 for the treatment of cutaneous T-cell lymphoma, with an interim analysis expected soon. This independent research coverage brings together clinical progress, financial positioning, and forward-looking catalysts into a cohesive perspective that reinforces the credibility of Soligenix's development strategy.</p><p>Beyond the FLASH2 study, the analysis underscores additional clinical and scientific developments that contribute to the depth of Soligenix's pipeline, offering investors detailed insights into the company's valuation potential. The report serves as analytical validation for Soligenix as its pipeline progress drives a forward outlook, with key milestones outlined that could significantly impact the company's trajectory. For those interested in following the latest developments, the company maintains an active newsroom where updates are regularly posted.</p><p>BioMedWire, the specialized communications platform publishing this content, operates as part of the Dynamic Brand Portfolio within IBN, delivering comprehensive distribution solutions across financial and biotech sectors. The platform provides enhanced press release services, social media distribution to millions of followers, and editorial syndication to over 5,000 outlets, ensuring that breaking news and insightful content about companies like Soligenix reaches a wide audience of investors, journalists, and the general public.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/3585bbbde487ee0d4aaca5bc5f07b256.30936.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/3585bbbde487ee0d4aaca5bc5f07b256.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//3585bbbde487ee0d4aaca5bc5f07b256'>Soligenix Gains Analytical Validation as Pipeline Progress Drives Forward Outlook.</a></p></div>        </article>    ", "published": "2026-04-15T13:05:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/3585bbbde487ee0d4aaca5bc5f07b256.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/3585bbbde487ee0d4aaca5bc5f07b256.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-6.jpg", "site_handle": "ibn", "seo_description": "Zacks analysis validates Soligenix's pipeline progress, highlighting HyBryte\u2122 phase 3 trial for cutaneous T-cell lymphoma and upcoming milestones driving forward outlook for investors.", "newsramp_curated": "https://newsramp.com/curated-news/soligenix-gains-analytical-validation-as-pipeline-progress-drives-forward-outlook/3585bbbde487ee0d4aaca5bc5f07b256"}, {"feed_item_id": 30911, "prhash_id": "537e9c66edce89d25200089f820659f3", "headline": "NeuroOne and University of Minnesota Pioneer sEEG-Based Epilepsy Drug Delivery", "content": "        <article>        <h1>NeuroOne and University of Minnesota Pioneer sEEG-Based Epilepsy Drug Delivery</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-7.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='NeuroOne and University of Minnesota Pioneer sEEG-Based Epilepsy Drug Delivery'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>NeuroOne's collaboration with the University of Minnesota could give the company a first-mover advantage in developing precise, brain-targeted epilepsy therapies that reduce systemic side effects.</li>            <li>The study uses NeuroOne's sEEG platform to deliver novel therapeutics directly into specific brain regions, aiming to improve efficacy while lowering toxicity through localized intracerebral infusion.</li>            <li>This research could lead to more precise, individualized epilepsy treatments that minimize side effects, offering patients better outcomes and improved quality of life through targeted brain therapy.</li>            <li>Scientists are testing ultra-thin electrodes to deliver drugs directly into seizure networks, potentially creating a new era of precision brain therapy for epilepsy patients.</li>        </ul>        <h2>Why it Matters</h2>        <p>This collaboration matters because it addresses a critical gap in epilepsy treatment by focusing on localized drug delivery, which could significantly reduce systemic side effects and improve precision for patients. Epilepsy affects millions worldwide, and current treatments often involve medications with broad impacts on the body, leading to adverse reactions and limited efficacy. By targeting specific brain regions involved in seizures, this approach has the potential to enhance therapeutic outcomes, minimize toxicity, and offer more personalized care. If successful, it could pave the way for new standards in neurological therapies, benefiting patients with drug-resistant epilepsy and reducing healthcare burdens through fewer hospitalizations and improved quality of life. This innovation aligns with broader trends in precision medicine, highlighting how advanced medical technologies can transform chronic disease management.</p>        <h2>Summary</h2>        <p><p>NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company specializing in neurological disorder treatments, has announced a groundbreaking collaboration with the University of Minnesota Medical School's Department of Neurology's Division of Epilepsy. This partnership aims to advance a study evaluating next-generation epilepsy therapies using NeuroOne's innovative sEEG-based platform for localized drug delivery. The program is led by Dr. Sandipan Pati, Professor and Epilepsy Division Director, who is at the forefront of epilepsy care and research, bringing academic expertise and clinical insight to this pioneering initiative.</p><p>The core focus of this collaboration is on testing novel therapeutics delivered directly into specific brain regions involved in sustaining seizures, with the goal of improving clinical efficacy while reducing systemic toxicity and off-target effects. The study is expected to begin with large animal models and, if primary objectives are met, progress to human studies shortly thereafter. Dr. Pati emphasized that localized intracerebral delivery represents an important emerging direction for enhancing precision in epilepsy treatment, potentially minimizing systemic side effects and offering more individualized therapies for patients. NeuroOne's President and CEO, Dave Rosa, highlighted the University of Minnesota's leadership in next-generation epilepsy research, expressing optimism that this collaboration could support the development of a first-in-human study utilizing their technology, which might redefine seizure care and establish a new era of precision brain-directed therapy.</p><p>NeuroOne's technology platform includes FDA-cleared products such as Evo\u00ae Cortical Electrodes, Evo\u00ae sEEG Electrodes, and the OneRF\u00ae Ablation System, which are designed to reduce hospitalizations, lower costs, and improve patient outcomes through combination diagnostic and therapeutic functions. The company is actively engaged in research and development for drug delivery and spinal cord stimulation programs, with more information available at nmtc1.com. This news release was distributed via NEWMEDIAWIRE, and the original release can be viewed on www.newmediawire.com, underscoring the significance of this collaboration in the medical technology and epilepsy treatment fields. The forward-looking statements in the release caution about potential risks and uncertainties, but the overall message points to a promising step toward transformative neurological care.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/537e9c66edce89d25200089f820659f3.30911.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/537e9c66edce89d25200089f820659f3.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/neuroone-r-advances-brain-drug-delivery-platform-through-collaboration-with-university-of-minnesota-7086352/537e9c66edce89d25200089f820659f3'>NeuroOne and University of Minnesota Pioneer sEEG-Based Epilepsy Drug Delivery.</a></p></div>        </article>    ", "published": "2026-04-15T12:30:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/537e9c66edce89d25200089f820659f3.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/537e9c66edce89d25200089f820659f3.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-7.jpg", "site_handle": "newmediawire", "seo_description": "NeuroOne partners with University of Minnesota to advance sEEG-based drug delivery for epilepsy, aiming to improve precision and reduce side effects in seizure treatment.", "newsramp_curated": "https://newsramp.com/curated-news/neuroone-and-university-of-minnesota-pioneer-seeg-based-epilepsy-drug-delivery/537e9c66edce89d25200089f820659f3"}, {"feed_item_id": 30905, "prhash_id": "662b7d72e35184c097306e489c90cf4f", "headline": "Carmed Pharmaceuticals Expands U.S. Reach with OneLavi Wellness Launch", "content": "        <article>        <h1>Carmed Pharmaceuticals Expands U.S. Reach with OneLavi Wellness Launch</h1>        <img src='https://us-southeast-1.linodeobjects.com/cdn.newsramp.app/banners/2357-1776191029777.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Carmed Pharmaceuticals Expands U.S. Reach with OneLavi Wellness Launch'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Carmed Pharmaceuticals gains a competitive edge by launching on OneLavi's curated marketplace, expanding U.S. access to its standardized botanical formulations for immune and cellular health.</li>            <li>Carmed Pharmaceuticals integrates traditional botanical knowledge with modern pharmaceutical methodology, using standardized processes and GMP manufacturing to ensure consistent, research-driven formulation quality.</li>            <li>Carmed's expansion onto curated platforms like OneLavi increases accessibility to science-informed wellness products, supporting preventive health and immune resilience for broader communities.</li>            <li>A Turkey-based company blends Anatolian botanical heritage with modern science to create standardized carvacrol formulations, now launching on the curated OneLavi marketplace.</li>        </ul>        <h2>Why it Matters</h2>        <p>This expansion matters because it brings scientifically-formulated, standardized botanical products to American consumers through a curated platform that prioritizes quality and transparency. As consumers increasingly seek evidence-based wellness solutions beyond traditional supplements, Carmed's research-driven approach combining traditional botanical knowledge with modern pharmaceutical methodology offers a new standard in the wellness industry. The availability of these formulations, particularly those that are gluten-free, non-GMO, and halal-certified, addresses growing demand for specialized health products that accommodate diverse dietary and lifestyle needs. Furthermore, the company's commitment to academic research and GMP manufacturing provides consumers with greater confidence in product quality and consistency, potentially raising industry standards for botanical formulations in the competitive U.S. wellness market.</p>        <h2>Summary</h2>        <p><p>Carmed Pharmaceuticals, a Turkey-based science-driven company specializing in standardized carvacrol-based formulations, is expanding its U.S. market presence with a strategic launch on OneLavi, a curated online marketplace for beauty, health, and wellness products. This move represents a significant step in Carmed's multi-channel distribution strategy, following their previously announced plans for Amazon availability, and reflects their commitment to building long-term credibility and accessibility in the American market. The company, which integrates traditional botanical knowledge with modern pharmaceutical methodology, focuses on developing research-driven formulations designed to support immune resilience, cellular health, and overall physiological balance through standardized processes that ensure consistency and quality control.</p><p>The OneLavi platform provides Carmed with a curated environment that emphasizes quality, transparency, and product discovery, allowing the company to position its formulations alongside premium wellness offerings. Mustafa Can, Founder of Carmed Pharmaceuticals, emphasized that this expansion aligns with their commitment to standardized development and consistent formulation quality. The launch will introduce several core formulations including Vacrol\u00ae Kids Spray for children's upper respiratory wellness, S-Mix\u00ae for immune function support, Vacrol\u00ae Capsule for microbial balance, Vacrol-M\u00ae Capsule for respiratory wellness, and Omevaq-3\u00ae for cellular energy metabolism and cognitive wellness. Notably, Vacrol\u00ae Kids Spray and S-Mix\u00ae are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified, meeting diverse consumer needs.</p><p>Carmed's approach is supported by ongoing scientific collaboration with academic institutions and researchers, including a January 2026 study published in the peer-reviewed journal Plants that examined Vacrol\u00ae and S-Mix\u00ae in preclinical models. The company emphasizes that this research contributes to scientific investigation of carvacrol-based formulations while maintaining regulatory compliance. Ceren Can, Global Brand Director, highlighted that the OneLavi launch is crucial for building awareness and accessibility while maintaining Carmed's standards of quality and research-driven development. With nearly 15 years of industry experience and GMP-compliant manufacturing, Carmed invites consumers to visit their website and Instagram for more information about their Anatolia-rooted botanical formulations that combine traditional plant knowledge with modern pharmaceutical technology.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/662b7d72e35184c097306e489c90cf4f.30905.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/662b7d72e35184c097306e489c90cf4f.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://newsworthy.ai'>Newsworthy.ai</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newsworthy/en/carmed-pharmaceuticals-expands-us-distribution-with-upcoming-launch-on-onelavi/662b7d72e35184c097306e489c90cf4f'>Carmed Pharmaceuticals Expands U.S. Reach with OneLavi Wellness Launch.</a></p></div>        </article>    ", "published": "2026-04-15T09:00:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/662b7d72e35184c097306e489c90cf4f.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/662b7d72e35184c097306e489c90cf4f.webp", "enclosure": "https://us-southeast-1.linodeobjects.com/cdn.newsramp.app/banners/2357-1776191029777.jpg", "site_handle": "newsworthy", "seo_description": "Carmed Pharmaceuticals launches carvacrol-based wellness formulations on OneLavi marketplace, expanding U.S. distribution with research-driven botanical products for immune and cellular health support.", "newsramp_curated": "https://newsramp.com/curated-news/carmed-pharmaceuticals-expands-u-s-reach-with-onelavi-wellness-launch/662b7d72e35184c097306e489c90cf4f"}, {"feed_item_id": 30906, "prhash_id": "658324044295020760a6fd3722ecf6c7", "headline": "Loneliness Linked to 19% Higher Risk of Degenerative Heart Valve Disease", "content": "        <article>        <h1>Loneliness Linked to 19% Higher Risk of Degenerative Heart Valve Disease</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-1.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Loneliness Linked to 19% Higher Risk of Degenerative Heart Valve Disease'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Addressing loneliness could provide a health advantage by reducing degenerative heart valve disease risk by up to 23%, potentially delaying costly surgical interventions.</li>            <li>A 14-year study of 463,000 UK Biobank participants found loneliness increases degenerative heart valve disease risk by 19-23%, independent of genetics and traditional risk factors.</li>            <li>Recognizing loneliness as a modifiable health risk could improve cardiovascular outcomes and reduce the societal burden of valvular heart disease through better social connection.</li>            <li>Loneliness, not social isolation, increases heart valve disease risk by 19-23%, with unhealthy lifestyle habits explaining part of this surprising connection.</li>        </ul>        <h2>Why it Matters</h2>        <p>This research matters because it identifies loneliness as a significant, potentially modifiable risk factor for a serious heart condition that affects millions, particularly as populations age. Unlike social isolation, which involves objective measures like living alone, loneliness is a subjective feeling of lacking meaningful connections\u2014something that can occur even in crowded rooms or with many online 'friends.' The study shows that chronic loneliness acts as a biological stressor, increasing the risk of degenerative heart valve disease by 19%, with even higher risks for specific valve problems like aortic stenosis and mitral regurgitation. This has direct implications for public health: by recognizing and addressing loneliness, healthcare providers and individuals could potentially delay disease progression, reduce the need for invasive surgeries like valve replacements, and improve overall quality of life. In an era where social disconnectedness is rising despite digital connectivity, this finding underscores that genuine human connection is not just emotionally fulfilling but physiologically protective, offering a new avenue for preventive cardiology that complements traditional lifestyle interventions.</p>        <h2>Summary</h2>        <p><p>Groundbreaking research published in the Journal of the American Heart Association reveals a significant link between loneliness and degenerative heart valve disease, a serious condition affecting the heart's valves. The study, led by researchers from The Second Xiangya Hospital in China and analyzing data from nearly 463,000 adults in the UK Biobank, found that adults reporting feelings of loneliness had a 19% higher risk of developing degenerative valvular heart disease over a median follow-up of nearly 14 years. This risk persisted even after accounting for traditional factors like genetics and lifestyle, with specific increases of 21% for aortic valve stenosis and 23% for mitral valve regurgitation. Notably, the research distinguished between loneliness\u2014a subjective feeling of lacking meaningful connection\u2014and objective social isolation, finding that isolation itself was not significantly associated with increased risk.</p><p>The study's key players include lead author Dr. Zhaowei Zhu and co-author Cheng Wei, who emphasize that loneliness may be an independent and modifiable risk factor for a disease that becomes more common with aging. American Heart Association expert Dr. Crystal Wiley Cene, who was not involved in the study but contributed context, stressed that loneliness is a biological stressor, not a moral failing. The research suggests unhealthy lifestyle habits like smoking and inactivity partially explain the link, but loneliness itself appears to exert a direct influence. With valvular heart disease accounting for over 440,000 U.S. deaths between 1999 and 2020, as noted in the American Heart Association's 2026 Heart Disease and Stroke Statistics Report, this finding highlights a critical public health concern.</p><p>This study represents one of the first large-scale examinations of loneliness's specific impact on valve health, building on prior AHA statements about social connection's role in cardiovascular health. The implications are profound: addressing loneliness could help delay disease progression, reduce the need for surgical interventions like valve replacement, and lessen the long-term clinical and economic burden. Researchers call for future studies to confirm findings in more diverse populations and explore biological mechanisms, while health professionals are encouraged to discuss loneliness as a legitimate health risk. The message is clear: meaningful social connections are vital for heart health, potentially offering a new pathway for prevention in an aging global population.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/658324044295020760a6fd3722ecf6c7.30906.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/658324044295020760a6fd3722ecf6c7.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/loneliness-linked-to-increased-risk-of-degenerative-heart-valve-disease-7086351/658324044295020760a6fd3722ecf6c7'>Loneliness Linked to 19% Higher Risk of Degenerative Heart Valve Disease.</a></p></div>        </article>    ", "published": "2026-04-15T09:00:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/658324044295020760a6fd3722ecf6c7.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/658324044295020760a6fd3722ecf6c7.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-1.jpg", "site_handle": "newmediawire", "seo_description": "New study finds loneliness increases risk of degenerative heart valve disease by 19%, even after accounting for genetics and lifestyle. Research highlights need to address social connection for heart health.", "newsramp_curated": "https://newsramp.com/curated-news/loneliness-linked-to-19-higher-risk-of-degenerative-heart-valve-disease/658324044295020760a6fd3722ecf6c7"}, {"feed_item_id": 30879, "prhash_id": "f526a300d1d3b3824dae3b5417a02fd3", "headline": "Soligenix Leverages Platform Science to Streamline Drug Development for Rare Diseases", "content": "        <article>        <h1>Soligenix Leverages Platform Science to Streamline Drug Development for Rare Diseases</h1>        <img src='https://cdn.newsramp.app/banners/business-corporate-4.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Soligenix Leverages Platform Science to Streamline Drug Development for Rare Diseases'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Soligenix's platform approach using synthetic hypericin gives it a strategic advantage in developing multiple treatments efficiently, potentially accelerating market entry and reducing development costs.</li>            <li>Soligenix leverages synthetic hypericin as a platform technology, streamlining development by using a shared mechanism across multiple dermatologic indications to reduce redundancy in preclinical and regulatory work.</li>            <li>Soligenix's platform-based drug development could bring faster, more affordable treatments for rare diseases like CTCL and psoriasis, improving patient outcomes and addressing unmet medical needs.</li>            <li>Soligenix uses synthetic hypericin as a versatile platform, treating conditions from CTCL to psoriasis while also developing vaccines with its heat stabilization technology.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it showcases how platform-based drug development can accelerate treatments for rare and underserved diseases, potentially reducing costs and time-to-market. For patients with conditions like cutaneous T-cell lymphoma or psoriasis, Soligenix's approach could lead to more accessible and effective therapies. In the broader biopharmaceutical industry, this strategy enhances efficiency and risk management, encouraging innovation that addresses unmet medical needs. Additionally, the company's public health vaccine programs, supported by government agencies, highlight its role in pandemic preparedness and biodefense, impacting global health security. Investors and stakeholders should note this as a model for sustainable growth in biotech.</p>        <h2>Summary</h2>        <p><p>Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is featured in a recent article highlighting its strategic use of platform-based drug development. The company exemplifies this approach through its synthetic hypericin platform, which is being leveraged across multiple dermatologic indications. This strategy allows Soligenix to streamline development processes, reduce redundancy in preclinical work and regulatory documentation, and expand clinical impact efficiently. The article emphasizes how platform technology serves as a foundational system for developing multiple products, particularly in life sciences, offering significant risk management advantages in the competitive biotech landscape.</p><p>Soligenix's Specialized BioTherapeutics segment is advancing HyBryte\u2122 (SGX301), a novel photodynamic therapy using synthetic hypericin for treating cutaneous T-cell lymphoma (CTCL), with regulatory approvals sought following successful Phase 3 studies. The company is also expanding synthetic hypericin into psoriasis (SGX302) and developing first-in-class innate defense regulator technology for inflammatory diseases. Additionally, Soligenix's Public Health Solutions segment includes vaccine candidates for ricin toxin, filoviruses like Marburg and Ebola, and CiVax\u2122 for COVID-19 prevention, utilizing its proprietary ThermoVax\u00ae heat stabilization platform. These programs are supported by government grants and contracts from agencies such as NIAID, DTRA, and BARDA, underscoring their strategic importance.</p><p>The article was published by MissionIR, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides syndicated content and corporate communications solutions to enhance company visibility. MissionIR offers access to wire solutions via InvestorWire, editorial syndication to over 5,000 outlets, press release enhancement, and social media distribution through IBN's network. For more details, readers can visit the full article at https://ibn.fm/Sbnv0 or explore Soligenix's newsroom at https://ibn.fm/SNGX. This coverage illustrates how innovative biopharmaceutical companies like Soligenix are leveraging platform science to address unmet medical needs in rare diseases and public health, potentially transforming treatment paradigms and improving patient outcomes worldwide.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/f526a300d1d3b3824dae3b5417a02fd3.30879.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/f526a300d1d3b3824dae3b5417a02fd3.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//f526a300d1d3b3824dae3b5417a02fd3'>Soligenix Leverages Platform Science to Streamline Drug Development for Rare Diseases.</a></p></div>        </article>    ", "published": "2026-04-14T17:38:37+00:00", "audio_release": "https://cdn.newsramp.net/audio/f526a300d1d3b3824dae3b5417a02fd3.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/f526a300d1d3b3824dae3b5417a02fd3.webp", "enclosure": "https://cdn.newsramp.app/banners/business-corporate-4.jpg", "site_handle": "ibn", "seo_description": "Soligenix uses synthetic hypericin platform for multiple dermatologic treatments, streamlining drug development. Learn about its CTCL therapy, vaccine programs, and platform science advantages in biopharma innovation.", "newsramp_curated": "https://newsramp.com/curated-news/soligenix-leverages-platform-science-to-streamline-drug-development-for-rare-diseases/f526a300d1d3b3824dae3b5417a02fd3"}, {"feed_item_id": 30888, "prhash_id": "c825f17459a864bb317426557fd1184a", "headline": "Breakthrough Glioblastoma Treatment Shows Promise in Preclinical Study", "content": "        <article>        <h1>Breakthrough Glioblastoma Treatment Shows Promise in Preclinical Study</h1>        <img src='https://cdn.newsramp.app/banners/science-4.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Breakthrough Glioblastoma Treatment Shows Promise in Preclinical Study'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>CNS Pharmaceuticals Inc. and other companies are advancing new glioblastoma treatments, offering potential investment opportunities in a field with high unmet medical need.</li>            <li>A preclinical study using animal models has identified a potential breakthrough treatment that could eliminate glioblastoma tumors, with human trials planned as the next phase.</li>            <li>This potential breakthrough could save lives by offering effective treatment for glioblastoma, a deadly brain cancer that currently kills patients within months.</li>            <li>After nearly two decades of stagnation, new preclinical research reveals a promising treatment that could eliminate aggressive glioblastoma brain tumors.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because glioblastoma is one of the most aggressive and lethal forms of brain cancer, with survival rates typically measured in months rather than years. For nearly two decades, treatment options have remained stagnant, leaving patients and families with limited hope. The potential breakthrough described here represents more than just scientific progress\u2014it could translate to extended survival and improved quality of life for thousands diagnosed annually. Beyond the immediate medical implications, successful development of effective glioblastoma treatments would reduce the devastating emotional and financial toll on families while advancing our understanding of brain cancer biology. The involvement of multiple research entities and the broad dissemination through specialized platforms like BioMedWire indicates growing momentum in a field that desperately needs innovation, potentially accelerating the timeline from laboratory discovery to clinical application.</p>        <h2>Summary</h2>        <p><p>A new preclinical study has revealed a potential breakthrough in treating glioblastoma, a deadly and fast-progressing brain cancer that has seen no significant treatment advances for nearly two decades. The research, conducted on animal models, shows promising results that could eliminate these aggressive tumors, offering hope where traditional approaches have failed. As the research team prepares to advance their approach through human clinical trials, other players like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also making strides in this critical field, indicating growing momentum in glioblastoma research.</p><p>The news comes from BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences developments. As part of the Dynamic Brand Portfolio at IBN, BioMedWire provides comprehensive distribution services including wire solutions through InvestorWire, editorial syndication to over 5,000 outlets, enhanced press release features, social media distribution to millions, and tailored corporate communications solutions. This extensive network ensures that breakthrough news like this glioblastoma treatment development reaches investors, journalists, and the public effectively, cutting through information overload to deliver actionable insights.</p><p>With glioblastoma typically killing victims within months of diagnosis, this potential breakthrough represents more than just scientific progress\u2014it offers tangible hope to patients and families facing this devastating diagnosis. The convergence of promising preclinical results and broader industry engagement through platforms like BioMedWire creates an environment where medical innovation can gain the visibility and support needed to move from laboratory success to real-world treatments. As research advances toward human trials, this development marks a significant step forward in addressing one of oncology's most challenging frontiers.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/c825f17459a864bb317426557fd1184a.30888.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/c825f17459a864bb317426557fd1184a.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//c825f17459a864bb317426557fd1184a'>Breakthrough Glioblastoma Treatment Shows Promise in Preclinical Study.</a></p></div>        </article>    ", "published": "2026-04-14T14:05:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/c825f17459a864bb317426557fd1184a.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/c825f17459a864bb317426557fd1184a.webp", "enclosure": "https://cdn.newsramp.app/banners/science-4.jpg", "site_handle": "ibn", "seo_description": "New preclinical study reveals promising glioblastoma treatment breakthrough after decades of stagnation. Learn about potential tumor elimination and advancing research in deadly brain cancer treatment.", "newsramp_curated": "https://newsramp.com/curated-news/breakthrough-glioblastoma-treatment-shows-promise-in-preclinical-study/c825f17459a864bb317426557fd1184a"}, {"feed_item_id": 30853, "prhash_id": "2bd0892da78fe87f43ba398d8789baff", "headline": "GeoVax Challenges Vaccine Monopoly to Boost Global Mpox and Smallpox Defense", "content": "        <article>        <h1>GeoVax Challenges Vaccine Monopoly to Boost Global Mpox and Smallpox Defense</h1>        <img src='https://cdn.newsramp.app/banners/industry-manufacturing-6.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='GeoVax Challenges Vaccine Monopoly to Boost Global Mpox and Smallpox Defense'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>GeoVax's GEO-MVA vaccine candidate offers a strategic advantage by breaking the current single-supplier monopoly, positioning itself as a second-source option in a market worth hundreds of millions annually.</li>            <li>GeoVax's GEO-MVA leverages the established MVA platform and follows a defined regulatory pathway via immuno-bridging, with Phase 3 trials planned for 2026 to address supply constraints.</li>            <li>Increasing global MVA vaccine supply through GeoVax's GEO-MVA candidate enhances preparedness for outbreaks, protects vulnerable populations, and strengthens worldwide public health security.</li>            <li>GeoVax is developing a second-source MVA vaccine to combat mpox and smallpox, targeting a market driven by recurring outbreaks and government stockpiling worth hundreds of millions.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it addresses a critical vulnerability in global health security. The current single-supplier market for MVA vaccines against mpox and smallpox creates a dangerous bottleneck, leaving populations unprotected during outbreaks and depleting government stockpiles. As seen with recent mpox outbreaks and the constant threat of biological agents, reliable vaccine access is not just a public health issue but a national security priority. GeoVax's effort to introduce a second-source vaccine could diversify supply, enhance surge capacity, and strengthen worldwide preparedness against these persistent viral threats, ultimately making outbreak response more resilient and protecting vulnerable communities.</p>        <h2>Summary</h2>        <p><p>GeoVax Labs, a clinical-stage biotechnology company, has issued a stark warning about the critical vulnerabilities in the global orthopoxvirus vaccine market, which targets diseases like mpox and smallpox. The company highlights that this is an active, procurement-driven market generating hundreds of millions of dollars annually, fueled by national stockpile programs, global health organization purchases, and outbreak-driven surge demand. However, the supply is dangerously concentrated with a single commercial supplier of Modified Vaccinia Ankara (MVA) vaccines, the preferred option for vulnerable populations. This monopoly has led to repeated stockpile depletions, limited surge capacity during outbreaks, and heightened risks to global health security, prompting governments worldwide to prioritize supply chain diversification and resilience.</p><p>In response to this urgent challenge, GeoVax is strategically positioning its GEO-MVA vaccine candidate as a potential second-source solution. The candidate leverages the established and safe MVA platform and is on a defined regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in 2026. The company believes GEO-MVA is uniquely timed to meet anticipated stockpile replenishment cycles and aligns with increasing policy emphasis on strengthening biosecurity infrastructure and ensuring reliable access to critical medical countermeasures. David Dodd, GeoVax's Chairman and CEO, emphasized that the market's recurring demand and strategic importance create a durable opportunity, not just a one-time pandemic response.</p><p>The news release, available on www.newmediawire.com, underscores that the mpox/smallpox vaccine market sits at the intersection of public health preparedness and national biodefense priorities. Recent outbreaks of more virulent mpox strains have reinforced the need for sustained vaccine supply beyond emergency cycles. GeoVax's broader pipeline includes other developments, but the focus here is on GEO-MVA's potential to support national stockpiles, global outbreak responses, and long-term biodefense strategies, thereby addressing a clear and present gap in global health security. For more information, visit the company's website at www.geovax.com.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/2bd0892da78fe87f43ba398d8789baff.30853.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/2bd0892da78fe87f43ba398d8789baff.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/geovax-positions-geo-mva-to-address-supply-constraints-in-global-mpox-and-smallpox-vaccine-market-7086335/2bd0892da78fe87f43ba398d8789baff'>GeoVax Challenges Vaccine Monopoly to Boost Global Mpox and Smallpox Defense.</a></p></div>        </article>    ", "published": "2026-04-14T13:00:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/2bd0892da78fe87f43ba398d8789baff.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/2bd0892da78fe87f43ba398d8789baff.webp", "enclosure": "https://cdn.newsramp.app/banners/industry-manufacturing-6.jpg", "site_handle": "newmediawire", "seo_description": "GeoVax Labs targets the constrained mpox/smallpox vaccine market with its GEO-MVA candidate, aiming to break the single-supplier monopoly and boost global health security.", "newsramp_curated": "https://newsramp.com/curated-news/geovax-challenges-vaccine-monopoly-to-boost-global-mpox-and-smallpox-defense/2bd0892da78fe87f43ba398d8789baff"}, {"feed_item_id": 30850, "prhash_id": "8238fabd3734f3fab4800fb6b0bf0c94", "headline": "Aclarion Wins Top AI Award for Chronic Back Pain Diagnostic Breakthrough", "content": "        <article>        <h1>Aclarion Wins Top AI Award for Chronic Back Pain Diagnostic Breakthrough</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-2.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Aclarion Wins Top AI Award for Chronic Back Pain Diagnostic Breakthrough'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Aclarion's award-winning Nociscan AI platform offers a competitive edge by targeting the costly chronic low back pain market with a 97% surgical success rate.</li>            <li>Nociscan uses MR spectroscopy to extract chemical biomarkers, which proprietary cloud-based algorithms analyze to classify discs as painful or non-painful for physicians.</li>            <li>This technology helps millions suffering from chronic low back pain by providing objective data to improve treatment planning and reduce healthcare costs.</li>            <li>Aclarion's Nociscan is the first evidence-supported SaaS platform that noninvasively distinguishes painful discs using biochemical biomarkers from MRI data.</li>        </ul>        <h2>Why it Matters</h2>        <p>This development matters because chronic low back pain represents one of the most significant healthcare burdens globally, affecting millions of people and costing healthcare systems billions annually in treatment expenses and lost productivity. Traditional diagnostic methods for discogenic pain often rely on subjective patient reports and imaging that may not accurately identify pain sources, leading to ineffective treatments, unnecessary procedures, and prolonged patient suffering. Aclarion's Nociscan technology addresses this critical gap by providing objective, biochemical data that helps physicians pinpoint the exact source of pain with greater accuracy. For patients, this means more targeted treatments, potentially higher success rates for interventions like surgery (97% success rate when Nociscan-positive discs are treated), and reduced trial-and-error approaches that delay relief. For healthcare systems, it offers the potential to reduce costs associated with ineffective treatments and repeated procedures while improving patient outcomes. The cloud-based nature of the platform also makes this advanced diagnostic capability accessible without major infrastructure investments, potentially democratizing access to precision spine care across different healthcare settings.</p>        <h2>Summary</h2>        <p><p>Aclarion, Inc., a commercial-stage healthcare technology company, has achieved significant recognition for its innovative approach to chronic low back pain diagnosis. The company recently received a Diamond Pinnacle Award for AI Innovation in the Clinical Decision AI category, following its earlier selection as a 2025 Digital Health Awards at HLTH winner. These accolades validate Aclarion's mission to bring objective, MR spectroscopy-based biomarker analysis into routine clinical decision-making through its flagship platform, Nociscan. This cloud-based SaaS solution uses proprietary augmented intelligence algorithms to analyze chemical biomarkers within intervertebral discs, helping physicians distinguish between painful and non-painful discs in the lumbar spine. The technology represents a breakthrough in addressing one of healthcare's most pervasive and costly challenges, with chronic low back pain affecting approximately 266 million people worldwide suffering from degenerative spine disease.</p><p>The core innovation lies in Nociscan's ability to provide physicians with objective biochemical data that complements traditional imaging and clinical evaluation. As CEO Brent Ness emphasized, this technology has the potential to fundamentally improve how discogenic pain is evaluated and treated. The platform operates through a cloud-based analytics system that can be rapidly deployed across imaging centers and health systems without requiring new hardware infrastructure, making it scalable and accessible. Clinical data demonstrates impressive results, with a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools. This evidence-supported approach marks a significant advancement in precision medicine for spine care, offering physicians more reliable tools for treatment planning.</p><p>Aclarion's growing recognition reflects the accelerating momentum behind their technology and its potential impact on the healthcare industry. The company continues to expand adoption of Nociscan among spine specialists seeking more objective tools for evaluating chronic low back pain. For those interested in learning more about this groundbreaking technology, additional information is available through the company's Latest News page and their contact email. The Pinnacle Awards 2026 AI Winners document provides further details about the award recognition, while the original press release distributed through PRISM MediaWire offers comprehensive coverage of this development in medical technology innovation.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/8238fabd3734f3fab4800fb6b0bf0c94.30850.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/8238fabd3734f3fab4800fb6b0bf0c94.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://prismmediawire.com'>PRISM Mediawire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/prism/en//8238fabd3734f3fab4800fb6b0bf0c94'>Aclarion Wins Top AI Award for Chronic Back Pain Diagnostic Breakthrough.</a></p></div>        </article>    ", "published": "2026-04-14T12:45:23+00:00", "audio_release": "https://cdn.newsramp.net/audio/8238fabd3734f3fab4800fb6b0bf0c94.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/8238fabd3734f3fab4800fb6b0bf0c94.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-2.jpg", "site_handle": "prism", "seo_description": "Aclarion wins Diamond Pinnacle Award for AI innovation in chronic low back pain diagnosis. Nociscan platform uses biomarkers & algorithms to identify painful discs with 97% surgical success rate when used with other tools.", "newsramp_curated": "https://newsramp.com/curated-news/aclarion-wins-top-ai-award-for-chronic-back-pain-diagnostic-breakthrough/8238fabd3734f3fab4800fb6b0bf0c94"}]}